Clinical Trials Directory

Trials / Completed

CompletedNCT02452216

Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

MR Imaging of Inflammatory Responses in the Central Nervous System With Ferumoxytol-Enhanced MRI

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
10 (actual)
Sponsor
Michael Iv · Academic / Other
Sex
All
Age
2 Years
Healthy volunteers
Not accepted

Summary

This pilot clinical trial study will assess the inflammatory response of brain tumors or other central nervous system conditions in pediatric and adult patients using ferumoxytol-enhanced MRI. Imaging features will be correlated with the number of inflammatory cells (macrophages) at histopathology. Determining the extent of inflammation associated with pathologies in the central nervous system may be helpful for diagnostic and prognostic purposes as well as monitoring treatment response of current and future immunotherapies.

Detailed description

In this study, we will establish the MR imaging characteristics of macrophages in malignant brain tumors and other CNS conditions in the pediatric and adult populations using ferumoxytol, an ultrasmall superparamagnetic iron oxide (USPIO) particle that is approved for the treatment of iron deficiency anemia in patients with chronic kidney disease. The investigators will correlate the MR signal of ferumoxytol uptake with the number of macrophages in surgical specimen at histopathology. This information may potentially offer clinicians a new means for risk stratification and monitoring treatment efficacy.

Conditions

Interventions

TypeNameDescription
DRUGFerumoxytolUndergo ferumoxytol-enhanced MRI
OTHERTissue AnalysisCorrelative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
PROCEDUREMagnetic Resonance ImagingAll subjects in the experimental arm who undergo ferumoxytol infusion will subsequently have MRI.

Timeline

Start date
2015-06-10
Primary completion
2017-01-12
Completion
2017-01-12
First posted
2015-05-22
Last updated
2017-08-31

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02452216. Inclusion in this directory is not an endorsement.